CF Foundation | Preclinical / New Technologies

371
Published on september 14, 2017 by

Before a potential new drug is tested in people with cystic fibrosis in clinical trials, it must go through preclinical development. Mike Boyle, M.D., our senior vice president of therapeutics development, shares an update on the exciting preclinical work the Foundation is doing for stop mutations, antibiotics, anti-inflammatories, and more.

Visit our Drug Development Pipeline: on.cff.org/pipeline

Visit our Clinical Trial Finder: on.cff.org/finder

Category

Add your comment

Your email address will not be published.